Chen Xiaoguang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8155586/publications.pdf

Version: 2024-02-01

63	1,716	394421	315739
papers	citations	19 h-index	38 g-index

63	63	63	2045
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ATF3 promotes erastin-induced ferroptosis by suppressing system Xcâ€“. Cell Death and Differentiation, 2020, 27, 662-675.	11.2	364
2	Long non-coding RNAs: From disease code to drug role. Acta Pharmaceutica Sinica B, 2021, 11, 340-354.	12.0	246
3	Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Scientific Reports, 2017, 7, 39011.	3.3	108
4	Skimmin, a Coumarin fromHydrangea paniculata, Slows down the Progression of Membranous Glomerulonephritis by Anti-Inflammatory Effects and Inhibiting Immune Complex Deposition. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	1.2	55
5	Coumarin glycosides from Hydrangea paniculata slow down the progression of diabetic nephropathy by targeting Nrf2 anti-oxidation and smad2/3-mediated profibrosis. Phytomedicine, 2019, 57, 385-395.	5.3	55
6	Total Coumarins from Hydrangea paniculata Show Renal Protective Effects in Lipopolysaccharide-Induced Acute Kidney Injury via Anti-inflammatory and Antioxidant Activities. Frontiers in Pharmacology, 2017, 8, 872.	3.5	53
7	Skimmin, a coumarin, suppresses the streptozotocin-induced diabetic nephropathy in wistar rats. European Journal of Pharmacology, 2012, 692, 78-83.	3.5	47
8	Stachybotrysins Aâ€“G, Phenylspirodrimane Derivatives from the Fungus Stachybotrys chartarum. Journal of Natural Products, 2017, 80, 1819-1826.	3.0	47
9	Sesquiterpenes from Artemisia argyi: Absolute Configurations and Biological Activities. European Journal of Organic Chemistry, 2014, 2014, 973-983.	2.4	42
10	Virtual Calibration Quantitative Mass Spectrometry Imaging for Accurately Mapping Analytes across Heterogenous Biotissue. Analytical Chemistry, 2019, 91, 2838-2846.	6.5	35
11	Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation . OncoTargets and Therapy, 2019, Volume 12, 883-896.	2.0	34
12	Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment. Journal of Medicinal Chemistry, 2018, 61, 6087-6109.	6.4	30
13	ATF3 promotes the serine synthesis pathway and tumor growth under dietary serine restriction. Cell Reports, 2021, 36, 109706.	6.4	29
14	Competitive ubiquitination activates the tumor suppressor p53. Cell Death and Differentiation, 2020, 27, 1807-1818.	11.2	27
15	Total Coumarins fromHydrangea paniculataProtect against Cisplatin-Induced Acute Kidney Damage in Mice by Suppressing Renal Inflammation and Apoptosis. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-15.	1.2	26
16	CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway. Cancer Letters, 2016, 381, 391-403.	7.2	25
17	Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. Journal of Drug Targeting, 2018, 26, 920-930.	4.4	22
18	Total coumarin derivates from Hydrangea paniculata attenuate renal injuries in cationized-BSA induced membranous nephropathy by inhibiting complement activation and interleukin 10-mediated interstitial fibrosis. Phytomedicine, 2022, 96, 153886.	5.3	22

#	Article	IF	Citations
19	Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis. Biochemical Pharmacology, 2014, 90, 50-61.	4.4	21
20	The pseudoginsenoside F11 ameliorates cisplatin-induced nephrotoxicity without compromising its anti-tumor activity in vivo. Scientific Reports, 2014, 4, 4986.	3.3	21
21	A Synthetic Manassantin A Derivative Inhibits Hypoxia-Inducible Factor 1 and Tumor Growth. PLoS ONE, 2014, 9, e99584.	2.5	19
22	Bistachybotrysins Aâ€“C, three phenylspirodrimane dimers with cytotoxicity from Stachybotrys chartarum. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 355-359.	2.2	19
23	Validating a Selective S1P₁ Receptor Modulator Syl930 for Psoriasis Treatment. Biological and Pharmaceutical Bulletin, 2018, 41, 592-596.	1.4	19
24	A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models. Acta Pharmaceutica Sinica B, 2020, 10, 276-288.	12.0	18
25	Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways. Current Cancer Drug Targets, 2014, 14, 671-683.	1.6	18
26	Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug. Pharmaceutics, 2021, 13, 598.	4.5	16
27	Cytotoxic dimeric xanthanolides from fruits of Xanthium chinense. Phytochemistry, 2016, 132, 115-122.	2.9	15
28	Chaperone-mediated autophagy degradation of IGF-1RÎ² induced by NVP-AUY922 in pancreatic cancer. Cellular and Molecular Life Sciences, 2019, 76, 3433-3447.	5.4	15
29	Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies. European Journal of Medicinal Chemistry, 2020, 190, 112079.	5.5	15
30	LXY6090 – a novel manassantin A derivative – limits breast cancer growth through hypoxia-inducible factor-1 inhibition. OncoTargets and Therapy, 2016, Volume 9, 3829-3840.	2.0	14
31	Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. Biochemical Pharmacology, 2016, 107, 29-40.	4.4	14
32	CAT₃, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O⁶-methylguanine DNA methyltransferase expression. OncoTargets and Therapy, 2018, Volume 11, 3671-3684.	2.0	14
33	Development and validation of high-throughput screening assays for poly(ADP-ribose) polymerase-2 inhibitors. Analytical Biochemistry, 2014, 449, 188-194.	2.4	13
34	Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways. Oncology Reports, 2017, 38, 2011-2022.	2.6	13
35	A New 2Î±,5Î±,10Î²,14Î²-tetraacetoxy-4(20),11-taxadiene (SIA) Derivative Overcomes Paclitaxel Resistance by Inhibiting MAPK Signaling and Increasing Paclitaxel Accumulation in Breast Cancer Cells. PLoS ONE, 2014, 9, e104317.	2.5	12
36	A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity. Cancer Letters, 2020, 495, 22-32.	7.2	12

#	Article	IF	Citations
37	Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. Bioorganic and Medicinal Chemistry, 2021, 29, 115890.	3.0	12
38	The novel anti-neuroblastoma agent PF403, inhibits proliferation and invasion in vitro and in brain xenografts. International Journal of Oncology, 2015, 47, 179-187.	3.3	10
39	Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis. Frontiers in Pharmacology, 2019, 10, 1085.	3.5	10
40	Secreted HSP90Î±-LRP1 Signaling Promotes Tumor Metastasis and Chemoresistance in Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 5532.	4.1	10
41	Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing 3-Substituted Piperizines as Potent PARP-1/2 Inhibitorsâ”€Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis. Journal of Medicinal Chemistry, 2021, 64, 16711-16730.	6.4	9
42	Simultaneous determination of skimmin, apiosylskimmin, 7â€hydroxycoumarin and 7â€hydroxycoumarin glucuronide in rat plasma by liquid chromatographyâ€“Orbitrap mass spectrometry and its application to pharmacokinetics. Biomedical Chromatography, 2022, 36, e5223.	1.7	8
43	Discovery of Benzocyclic Sulfone Derivatives as Potent CXCR2 Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 16626-16640.	6.4	8
44	A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models. Acta Pharmaceutica Sinica B, 2022, 12, 774-786.	12.0	7
45	A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo. Frontiers in Pharmacology, 2021, 12, 741697.	3.5	7
46	Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3KÎ´ Inhibitors for the Treatment of B-Cell Malignancies. Journal of Medicinal Chemistry, 2022, 65, 8011-8028.	6.4	7
47	Nicousamide normalizes renovascular hypertension in two-kidney one-clip hypertensive rats. Biomedical Reports, 2013, 1, 89-92.	2.0	6
48	Renal-protective effect of nicousamide on hypertensive nephropathy in spontaneously hypertensive rats. Biomedical Reports, 2013, 1, 34-40.	2.0	6
49	Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds. Chemistry and Biology, 2015, 22, 957-964.	6.0	6
50	Synthesis and anti-proliferative activity evaluation of sorafenib derivatives with a 3-arylacryloyl hydrazide unit. Medicinal Chemistry Research, 2015, 24, 1733-1743.	2.4	6
51	Identification of potential indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors by an FBG-based 3D QSAR pharmacophore model. Journal of Molecular Graphics and Modelling, 2020, 99, 107628.	2.4	6
52	Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies. Frontiers in Pharmacology, 2021, 12, 677120.	3.5	6
53	Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 637-646.	3.0	5
54	Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors. Molecules, 2020, 25, 1447.	3.8	5

#	Article	IF	Citations
55	The Development of a Biotinylated NAD+-Applied Human Poly(ADP-Ribose) Polymerase 3 (PARP3) Enzymatic Assay. SLAS Discovery, 2018, 23, 545-553.	2.7	4
56	A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC. Journal of Drug Targeting, 2019, 27, 451-459.	4.4	4
57	Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127508.	2.2	4
58	Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors. European Journal of Medicinal Chemistry, 2021, 223, 113634.	5.5	4
59	The PI3K Inhibitor XH30 Enhances Response to Temozolomide in Drug-Resistant Glioblastoma via the Noncanonical Hedgehog Signaling Pathway. Frontiers in Pharmacology, 2021, 12, 749242.	3.5	4
60	Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors. European Journal of Medicinal Chemistry, 2022, 234, 114252.	5.5	3
61	L-519, a phenolic compound, inhibits metabolism of benzo(a)pyrene and mutagenesis induced by benzo(a)pyrene. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1995, 7, 5-9.	2.2	2
62	Isolation and structural elucidation of bioactive obovatol dimeric neolignans from the bark of Magnolia officinalis var. biloba. Phytochemistry, 2022, 194, 113020.	2.9	2
63	Effects of limonene, salvia miltiorrhiza and turmeric derivatives on H-ras oncogene expression and gap junction intercellular communication in human solid tumor cell lines. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1998, 10, 162-168.	2.2	0